A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: alternate-day administration of S-1 plus leucovorin with bevacizumab Primary outcome(s): recommended dose Study Design: Single arm Non-randomized
干预措施：采用替吉奥（S-1）联合亚叶酸钙（leucovorin）与贝伐珠单抗（bevacizumab）的隔日给药方案 主要结局指标：推荐剂量 研究设计：单臂非随机化研究
创建时间：
2015-01-15
